BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $263,893 | +0.6% | 37,273 | -0.0% | 0.00% | 0.0% |
Q2 2023 | $262,416 | +11.1% | 37,275 | +31.6% | 0.00% | 0.0% |
Q1 2023 | $236,272 | -22.8% | 28,330 | +6.2% | 0.00% | -50.0% |
Q4 2022 | $306,137 | -4.0% | 26,667 | +5.3% | 0.00% | 0.0% |
Q3 2022 | $319,000 | +19.0% | 25,322 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $268,000 | -35.0% | 25,322 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $412,000 | -2.6% | 25,322 | -17.1% | 0.00% | 0.0% |
Q4 2021 | $423,000 | +9.6% | 30,547 | +13.8% | 0.00% | 0.0% |
Q3 2021 | $386,000 | -8.7% | 26,832 | +0.2% | 0.00% | 0.0% |
Q2 2021 | $423,000 | +70.6% | 26,766 | +9.9% | 0.00% | +100.0% |
Q1 2021 | $248,000 | +40.1% | 24,353 | +2.4% | 0.00% | 0.0% |
Q4 2020 | $177,000 | +115.9% | 23,789 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $82,000 | -27.4% | 23,789 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $113,000 | +222.9% | 23,789 | +35.5% | 0.00% | – |
Q1 2020 | $35,000 | +66.7% | 17,560 | +184.7% | 0.00% | – |
Q4 2019 | $21,000 | +16.7% | 6,168 | 0.0% | 0.00% | – |
Q3 2019 | $18,000 | -21.7% | 6,168 | 0.0% | 0.00% | – |
Q2 2019 | $23,000 | -54.0% | 6,168 | 0.0% | 0.00% | – |
Q1 2019 | $50,000 | 0.0% | 6,168 | 0.0% | 0.00% | -100.0% |
Q4 2018 | $50,000 | +6.4% | 6,168 | 0.0% | 0.00% | – |
Q3 2018 | $47,000 | +34.3% | 6,168 | 0.0% | 0.00% | – |
Q2 2018 | $35,000 | +20.7% | 6,168 | 0.0% | 0.00% | – |
Q1 2018 | $29,000 | -3.3% | 6,168 | 0.0% | 0.00% | – |
Q4 2017 | $30,000 | +233.3% | 6,168 | +242.5% | 0.00% | – |
Q3 2017 | $9,000 | -10.0% | 1,801 | 0.0% | 0.00% | – |
Q2 2017 | $10,000 | -33.3% | 1,801 | 0.0% | 0.00% | – |
Q1 2017 | $15,000 | +36.4% | 1,801 | 0.0% | 0.00% | – |
Q4 2016 | $11,000 | +37.5% | 1,801 | 0.0% | 0.00% | – |
Q3 2016 | $8,000 | +60.0% | 1,801 | 0.0% | 0.00% | – |
Q2 2016 | $5,000 | 0.0% | 1,801 | 0.0% | 0.00% | – |
Q1 2016 | $5,000 | -73.7% | 1,801 | 0.0% | 0.00% | – |
Q4 2015 | $19,000 | +137.5% | 1,801 | +166.8% | 0.00% | – |
Q3 2015 | $8,000 | – | 675 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |